» Articles » PMID: 35581423

A Computational Platform Integrating a Mechanistic Model of Crohn's Disease for Predicting Temporal Progression of Mucosal Damage and Healing

Abstract

Introduction: Physicians are often required to make treatment decisions for patients with Crohn's disease on the basis of limited objective information about the state of the patient's gastrointestinal tissue while aiming to achieve mucosal healing. Tools to predict changes in mucosal health with treatment are needed. We evaluated a computational approach integrating a mechanistic model of Crohn's disease with a responder classifier to predict temporal changes in mucosal health.

Methods: A hybrid mechanistic-statistical platform was developed to predict biomarker and tissue health time courses in patients with Crohn's disease. Eligible patients from the VERSIFY study (n = 69) were classified into archetypical response cohorts using a decision tree based on early treatment data and baseline characteristics. A virtual patient matching algorithm assigned a digital twin to each patient from their corresponding response cohort. The digital twin was used to forecast response to treatment using the mechanistic model.

Results: The responder classifier predicted endoscopic remission and mucosal healing for treatment with vedolizumab over 26 weeks, with overall sensitivities of 80% and 75% and overall specificities of 69% and 70%, respectively. Predictions for changes in tissue damage over time in the validation set (n = 31), a measure of the overall performance of the platform, were considered good (at least 70% of data points matched), fair (at least 50%), and poor (less than 50%) for 71%, 23%, and 6% of patients, respectively.

Conclusion: Hybrid computational tools including mechanistic components represent a promising form of decision support that can predict outcomes and patient progress in Crohn's disease.

Citing Articles

Combining mechanistic modeling with machine learning as a strategy to predict inflammatory bowel disease clinical scores.

Shim J, Rehberg M, Wagenhuber B, van der Graaf P, Chung D Front Pharmacol. 2025; 16:1479666.

PMID: 40070575 PMC: 11893853. DOI: 10.3389/fphar.2025.1479666.


Artificial intelligence use for precision medicine in inflammatory bowel disease: a systematic review.

Ceccato H, Silva T, Genaro L, Silva J, de Souza W, Oliveira P Am J Transl Res. 2025; 17(1):28-46.

PMID: 39959235 PMC: 11826164. DOI: 10.62347/XILL3707.


Digital Twins for Clinical and Operational Decision-Making: Scoping Review.

Riahi V, Diouf I, Khanna S, Boyle J, Hassanzadeh H J Med Internet Res. 2025; 27:e55015.

PMID: 39778199 PMC: 11754991. DOI: 10.2196/55015.


Augmented intelligence in precision medicine: Transforming clinical decision-making with AI/ML and/or quantitative systems pharmacology models.

Venkatapurapu S, Gibbs M, Kimko H Clin Transl Sci. 2024; 17(12):e70112.

PMID: 39673165 PMC: 11645444. DOI: 10.1111/cts.70112.


Definitions and Characteristics of Patient Digital Twins Being Developed for Clinical Use: Scoping Review.

Drummond D, Gonsard A J Med Internet Res. 2024; 26:e58504.

PMID: 39536311 PMC: 11602770. DOI: 10.2196/58504.


References
1.
Bower J, Lazo M, Juraschek S, Selvin E . Within-person variability in high-sensitivity C-reactive protein. Arch Intern Med. 2012; 172(19):1519-21. PMC: 3613132. DOI: 10.1001/archinternmed.2012.3712. View

2.
Hernandez-Lemus E, Siqueiros-Garcia J . Mechanistic-enriched models: integrating transcription factor networks and metabolic deregulation in cancer. Theor Biol Med Model. 2015; 12:16. PMC: 4565005. DOI: 10.1186/s12976-015-0012-3. View

3.
Siegel C, Horton H, Siegel L, K D Thompson , Mackenzie T, Stewart S . A validated web-based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables. Aliment Pharmacol Ther. 2015; 43(2):262-71. DOI: 10.1111/apt.13460. View

4.
Hibi T, Ogata H . Novel pathophysiological concepts of inflammatory bowel disease. J Gastroenterol. 2006; 41(1):10-6. DOI: 10.1007/s00535-005-1744-3. View

5.
Viceconti M, Pappalardo F, Rodriguez B, Horner M, Bischoff J, Musuamba Tshinanu F . In silico trials: Verification, validation and uncertainty quantification of predictive models used in the regulatory evaluation of biomedical products. Methods. 2020; 185:120-127. PMC: 7883933. DOI: 10.1016/j.ymeth.2020.01.011. View